370-50-3

Usage

Uses

Used in Agricultural Industry:
FLUCOFURON is used as a pesticide for its potent pesticidal utility against a variety of pests. It is particularly effective against pests belonging to the phyla Arthropoda, Mollusca, and Nematoda, providing a reliable solution for protecting crops and maintaining agricultural productivity. By targeting these specific groups of pests, FLUCOFURON helps to minimize crop damage and ensure a healthy yield, contributing to the overall success of the agricultural sector.

InChI:InChI=1/C15H8Cl2F6N2O/c16-11-3-1-7(5-9(11)14(18,19)20)24-13(26)25-8-2-4-12(17)10(6-8)15(21,22)23/h1-6H,(H2,24,25,26)

Upstream product

• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 102-09-0 bis(phenyl) carbonate 
• 75-44-5 phosgene 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 57-13-6 urea 
• 1885-14-9 phenyl chloroformate 

Relevant academic research and scientific papers

Pentafluorosulfanyl-containing triclocarban analogs with potent antimicrobial activity

Concerns have been raised about the long-term accumulating effects of triclocarban, a polychlorinated diarylurea widely used as an antibacterial soap additive, in the environment and in human beings. Indeed, the Food and Drug Administration has recently banned it from personal care products. Herein, we report the synthesis, antibacterial activity and cytotoxicity of novel N,N'-diarylureas as triclocarban analogs, designed by reducing one or more chlorine atoms of the former and/or replacing them by the novel pentafluorosulfanyl group, a new bioisostere of the trifluoromethyl group, with growing importance in drug discovery. Interestingly, some of these pentafluorosulfanyl-bearing ureas exhibited high potency, broad spectrum of antimicrobial activity against Gram-positive bacterial pathogens, and high selectivity index, while displaying a lower spontaneous mutation frequency than triclocarban. Some lines of evidence suggest a bactericidal mode of action for this family of compounds.

COMPOUND HAVING PROTEIN TYROSINE PHOSPHATASE SHP-1 AGONIST ACTIVITY

A compound having a chemical structure of formula I, wherein n is 0 or 1, X is N or C-R1, R1 is H or Cl, R2 and R3 are independently H, a halogen or an alkyl group, Ar is a substituted or unsubstituted phenylene or naphthylene group, with the substituted or unsubstituted phenylene group being A or B, and the naphthylene group being C, R4 is H, a halogen or an alkyl group, R5 is H, a halogen, an alkyl group, an alkoxyl group or a hydroxyl group, R6 is H or a hydroxyl group, and R7 is a substituted or unsubstituted aryl group. The compound has SHP-1 agonist activity, and can be used to treat cancer.

Antischistosomal activity of N,N′-arylurea analogs against Schistosoma japonicum

Although the antischistosomal activities of N,N′-arylurea analogs were reported, systematic structure-activity relationships have not been conducted. In this Letter, we reported the design, synthesis and evaluation of 45 N,N′-arylurea analogs. Among these prepared compounds, 13 compounds were urea linker modified and 32 were N,N′-arylurea derivatives. The activity evaluation revealed 12 analogs exhibited IC50 values lower than 22.6 μM, and 7 of them had IC50 less than 10 μM against the juvenile Schistosoma japonicum in vitro. Their worm killing potency was even higher against adult worm. Unfortunately, low to moderate worm burden reduction of 0-33.4% was recorded after administration of a single oral dose of 200 mg/kg or 400 mg/kg to mice harboring S. japonicum.

N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

In vitro inhibition of translation initiation by N,N′-diarylureas - Potential anti-cancer agents

Symmetrical N,N′-diarylureas: 1,3-bis(3,4-dichlorophenyl)-, 1,3-bis[4-chloro-3-(trifluoromethyl)phenyl]- and 1,3-bis[3,5- bis(trifluoromethyl)phenyl]urea, were identified as potent activators of the eIF2α kinase heme regulated inhibitor. They reduce the abundance of the eIF2·GTP·tRNAiMet ternary complex and inhibit cancer cell proliferation. An optimization process was undertaken to improve their solubility while preserving their biological activity. Non-symmetrical hybrid ureas were generated by combining one of the hydrophobic phenyl moieties present in the symmetrical ureas with the polar 3-hydroxy-tolyl moiety. O-alkylation of the later added potentially solubilizing charge bearing groups. The new non-symmetrical N,N′-diarylureas were characterized by ternary complex reporter gene and cell proliferation assays, demonstrating good bioactivities. A representative sample of these compounds potently induced phosphorylation of eIF2α and expression of CHOP at the protein and mRNA levels. These inhibitors of translation initiation may become leads for the development of potent, non-toxic, and target specific anti-cancer agents.

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.